文献速递心律失常

非维生素K拮抗剂口服抗凝药患者房颤导管消融术中抗凝管理:证据缺口的解读

Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
PubMed 文献 · Circulation · 2018-01-01

综述聚焦房颤导管消融术中接受非维生素K拮抗剂口服抗凝药(NOAC)患者的抗凝管理。最新国际指南推荐不间断NOAC并调整普通肝素使活化凝血时间(ACT)≥300秒,但近期经验提示NOAC患者较维生素K拮抗剂患者需更多肝素达标,证据存在缺口。

要点

  • 指南推荐房颤消融时不间断NOAC并调整肝素维持ACT≥300秒。
  • NOAC患者较维生素K拮抗剂患者可能需要更多普通肝素以达到目标ACT。
  • 需理解ACT监测的局限性及NOAC与维生素K拮抗剂的抗凝生理差异。

核心结论

  • 房颤导管消融术中NOAC患者的理想抗凝管理存在重要证据缺口,需审慎对待ACT监测的局限性。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 观察性研究和随机对照试验支持不间断NOAC策略用于房颤导管消融的安全性和有效性。
  • 近期经验显示NOAC治疗患者较维生素K拮抗剂治疗患者需要更多普通肝素以达到目标ACT。

关键数值与推荐

  • 最新国际指南推荐房颤导管消融时采用不间断NOAC并同时给予普通肝素,调整剂量以达到并维持目标ACT≥300秒。

临床怎么用

  • 临床行房颤导管消融时应遵循指南采用不间断NOAC策略,并监测ACT以调整普通肝素剂量。
  • 需认识到NOAC患者可能需要更高肝素剂量达标,并关注ACT监测的准确性局限。

局限性

  • 综述指出现有证据在NOAC患者术中抗凝管理方面存在重要缺口,ACT监测的准确性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Catheter ablation has gained a prominent role in the management of atrial fibrillation (AF), with recent data providing positive evidence on hard outcomes, including hospitalization and mortality. Ablation, however, exposes the patient to a rather unique situation, combining risks for both major bleeding and thromboembolic events. In this setting, the critical importance of rigorous anticoagulation during the procedure has been underlined, and the latest international guidelines now recommend performing AF catheter ablation with uninterrupted non-vitamin K antagonist oral anticoagulants (NOACs) and concomitant administration of unfractionated heparin adjusted to achieve and maintain a target activated clotting time of ≥300 seconds. Whereas observational studies and randomized controlled trials support the safety and efficacy of uninterrupted NOAC strategy for AF catheter ablation, recent experiences have questioned this point, showing a greater unfractionated heparin requirement in NOAC-treated patients compared with vitamin K antagonists-treated patients to achieve the target activated clotting time. Important gaps in evidence regarding optimal intraprocedural anticoagulation management need to be acknowledged. A thorough appreciation of the physiology of anticoagulation during AF catheter ablation and the relevant differences between vitamin K antagonists and NOACs is required, while also understanding the limitations of activated clotting time measurement with regard to accurate intraprocedural anticogulation monitoring. This review aims to provide a critical look at this relatively ignored aspect of AF catheter ablation, especially pitfalls in NOAC monitoring, and to identify gaps in knowledge that need to be addressed in the near future.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Martin AC, Godier A, Narayanan K, et al. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. Circulation. 2018. PMID: 30354610. doi:10.1161/CIRCULATIONAHA.117.033326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。